Erschienen in:
29.08.2019 | Original Article – Clinical Oncology
Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning
verfasst von:
Niels Smedegaard Andersen, Martin Bornhäuser, Martin Gramatzki, Peter Dreger, Antonin Vitek, Michal Karas, Mauricette Michallet, Carol Moreno, Michel van Gelder, Anja Henseler, Liesbeth C. de Wreede, Stefan Schönland, Nicolaus Kröger, Johannes Schetelig, the CLL subcommittee, Chronic Malignancies Working Party
Erschienen in:
Journal of Cancer Research and Clinical Oncology
|
Ausgabe 11/2019
Einloggen, um Zugang zu erhalten
Abstract
Purpose
The optimal dose intensity for conditioning prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) for chronic lymphocytic leukemia (CLL) is unknown.
Methods
We retrospectively compared outcomes of patients who received a first alloHCST after non-myeloablative (NMA) and reduced intensity conditioning (RIC). Data of 432 patients with a median age of 55 years were included, of which 86 patients underwent NMA and 346 RIC.
Results
The median follow-up after alloHSCT was 4.3 years. Compared to the RIC group, more NMA patients had purine-analog-sensitive disease, were in complete remission and received matched related donor transplantation. After RIC, the probabilities for 5-year OS, EFS, CIR, and NRM were 46%, 38%, 28%, and 35% and after NMA the respective probabilities were 52%, 43%, 25%, and 32%. In multivariate analysis, remission status prior to conditioning but not RIC versus NMA conditioning had a significant impact on CIR, EFS, and OS.
Conclusion
Presumed higher anti-leukemic activity of RIC versus NMA conditioning did not translate into better outcomes after alloHSCT, but better remission status prior to conditioning did. Effective pathway inhibitor-based salvage therapies combined with NMA conditioning might thus represent the most attractive contemporary approach for alloHSCT for patients with CLL.